CELESTIAL-TN CLL (NCT06073821) is a global, Phase 3, open-label, randomized trial comparing sonrotoclax plus zanubrutinib with venetoclax plus obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL).